Related references
Note: Only part of the references are listed.Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation
G. W. Basak et al.
BONE MARROW TRANSPLANTATION (2013)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)
Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant
Karen K. Ballen et al.
BLOOD (2012)
Three decades of transplantation for chronic myeloid leukemia: what have we learned?
Jiri Pavlu et al.
BLOOD (2011)
Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia
Hiroshi Yagasaki et al.
BLOOD (2011)
The EBMT activity survey 2009: trends over the past 5 years
H. Baldomero et al.
BONE MARROW TRANSPLANTATION (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Molecular methods in diagnosis and monitoring of haematological malignancies
David T. Yeung et al.
PATHOLOGY (2011)
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
Adam J. Mead et al.
BLOOD (2010)
Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions
D. Roos-Weil et al.
BONE MARROW TRANSPLANTATION (2010)
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Hee-Je Kim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors
D. A. Rizzieri et al.
BONE MARROW TRANSPLANTATION (2009)
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet
Marie C. Bene et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia
Mukta Arora et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML
C. F. Craddock
BONE MARROW TRANSPLANTATION (2008)
Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
A. Toor et al.
BONE MARROW TRANSPLANTATION (2008)
Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia
Xiao-Jun Huang et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation
A. W. Loren et al.
BONE MARROW TRANSPLANTATION (2008)
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria et al.
BLOOD (2007)
Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation
R. Or et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Hematopoietic stem cell donor selection: the Europdonor experience
M. Ouldshoorn et al.
HUMAN IMMUNOLOGY (2006)
Dose-escalated donor lymphocyte inftisions following reduced intensity transplantation: toxicity, chimerism, and disease responses
KS Peggs et al.
BLOOD (2004)
Share Paper
